Recently, an optimized ADCC-inducing anti-CD25 antibody showed superior intratumoral Treg depletion and induced CD8+ T cell–mediated tumor rejection in combination with anti-PD-1 therapy in preclinical models (Arce Vargas et al. 2017). The gene discussed is CD8A; the disease is neoplasm.